NOV 08, 2021 9:00 AM PST

A case study of CBD's tumor shrinking potential

WRITTEN BY: Kerry Charron

A recent article published in the British Medical Journal reported the case of a woman who shrank a tumor by taking CBD. Serial imaging shows the tumor decreased from 41 to 10 millimeters in just 2.5 years. The patient took .5ml of CBD oil two or three times a day. She declined conventional lung cancer treatments which usually involve chemotherapy, surgery, and radiotherapy and opted for following this specific CBD dosing schedule. This case study and other trial tests suggest cannabidiol oil may be highly effective in reducing the overall size of certain types of tumors.

CBD has been widely used for symptoms such as insomnia and anxiety, but emerging research data highlights potential therapeutic uses for oncology patients. Specifically, CBD can provide tumor management as well as reduction of other symptoms such as nausea and discomfort. Patient anecdotal evidence highlights many therapuetic benefits of CBD, but recent research attention has focused on how CBD impacts cancerous cell growth.

Studies on brain tumors conducted by University of Leeds researchers indicate that cannabis oil can reduce aggressive cancerous growth. Phase I of the trial test determined that CBD has anti-tumor properties. Phase II of this trial test will involve 15 National Institute of Health hospitals. 223 study participants will self-administer an oromucosal spray which consists of a 1:1 CBD to THC ratio up to 12 sprays per day. Participants will be asked to complete a quality-of-life questionnaire in addition to monthly medical checkups. This study will be one of the first trials to integrate with BRIAN, an app supporting those living with a brain tumor.

Phase II will examine the effects of adding Sativex to the current standard chemotherapy treatment (temozolomide) on the survival time for adults with glioblastoma. Glioblastoma is the most common type of brain tumor in adults, and it is characterized by fast growth and formations that are tendril-like. Recurring growth after surgery or radiation therapy is common, and the survival time after diagnosis is roughly 12-18 months. Researchers are hopeful that this study will lead to advances in CBD use for tumor regression, improved quality of life, and life extension for those living with brain cancer tumors. 

 

Sources: British Medical JournalUniversity of LeedsNature

About the Author
  • Kerry Charron writes about medical cannabis research. She has experience working in a Florida cultivation center and has participated in advocacy efforts for medical cannabis.
You May Also Like
NOV 05, 2021
Cannabis Sciences
THC & ASD: A Crucial Contributor to Symptom Alleviation
NOV 05, 2021
THC & ASD: A Crucial Contributor to Symptom Alleviation
Up until recently, cannabis-based treatments for Autism Spectrum Disorder (ASD) have focused on CBD-enrichment and THC d ...
NOV 08, 2021
Coronavirus
Pfizer Claims Their New COVID-19 Pill Reduces Hospitalization Risk by 89%
NOV 08, 2021
Pfizer Claims Their New COVID-19 Pill Reduces Hospitalization Risk by 89%
Current treatments for COVID-19 have to be administered intravenously, so a pill that could treat patients would be huge ...
NOV 20, 2021
Neuroscience
Fear balance - the brain and body communicate to maintain fear within an adaptive range
NOV 20, 2021
Fear balance - the brain and body communicate to maintain fear within an adaptive range
We have all experienced the emotion of fear. Although what one individual might fear (e.g. rollercoasters or snakes), mi ...
NOV 22, 2021
Health & Medicine
Can Nanotechnology Prevent Corneal Graft Rejection?
NOV 22, 2021
Can Nanotechnology Prevent Corneal Graft Rejection?
The cornea is among the essential anatomic features of the eye, responsible for most of the eye’s focusing ability ...
DEC 05, 2021
Microbiology
Researchers Find a Lyme Disease Diagnostic & Treatment Target
DEC 05, 2021
Researchers Find a Lyme Disease Diagnostic & Treatment Target
Ticks that carry Lyme disease can be found in more and more places. If a tick is infected with the bacterium that causes ...
DEC 03, 2021
Drug Discovery & Development
FDA approves new imaging drug to make ovarian cancer tumors glow.
DEC 03, 2021
FDA approves new imaging drug to make ovarian cancer tumors glow.
Earlier this week, the United States Food and Drug Administration (FDA) announced its approval for a novel dru ...
Loading Comments...